1-2 of 2
Thomas Perretti, MD MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies

Andrew K McMillan, FRCP, Matthew J Matasar, MD, Juan-Manuel Sancho, MD PhD, Andreas Viardot, MD PhD, Juana Hernandez, MD, Thomas Perretti, MD MSc, Corinne Haioun, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5317.
https://doi.org/10.1182/blood-2019-123673
Published: 2019
Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3035.
https://doi.org/10.1182/blood-2019-123419
Published: 2019